Open Orphan PLC
LSE:ORPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (2.5), the stock would be worth GBX10 (0% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.5 | GBX10 |
0%
|
| 3-Year Average | 2.5 | GBX10 |
0%
|
| 5-Year Average | 2.5 | GBX10 |
0%
|
| Industry Average | 0 | GBX0.11 |
-99%
|
| Country Average | 0 | GBX0.1 |
-99%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
O
|
Open Orphan PLC
LSE:ORPH
|
67.1m GBP | 2.5 | -86.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 774.1 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
175.6B USD | 25.5 | 26.2 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.4B USD | 21.5 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 36.2 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 15.4 | 15.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 31.3 | -119.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.3B USD | 24.3 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.5B USD | 47.3 | 47.5 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.3B USD | 14.7 | 20.1 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | 29 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 2 105.8 |
Other Multiples
Open Orphan PLC
Glance View
Open Orphan Plc provides pharmaceutical development services. The firm is engaged in the testing of vaccines and antivirals using human clinical trials. The firm has a presence in the United Kingdom, Ireland, France and Netherlands. The Company, through its subsidiary hVIVO Limited, is also engaged in the data platform business. hVIVO Limited has built up databases of infectious disease progression data and the Company is populating its Open Orphan Health Data platform with hVIVO data. The firm also operates through its subsidiary Venn Life Sciences, which is an integrated drug development partner. Venn Life Sciences offers a combination of drug development consultancy, clinical trial design and execution to create, plan and execute drug development programs for its customers.
